Intra-tumor heterogeneity: lessons from microbial evolution and clinical implications
Tóm tắt
Multiple subclonal populations of tumor cells can coexist within the same tumor. This intra-tumor heterogeneity will have clinical implications and it is therefore important to identify factors that drive or suppress such heterogeneous tumor progression. Evolutionary biology can provide important insights into this process. In particular, experimental evolution studies of microbial populations, which exist as clonal populations that can diversify into multiple subclones, have revealed important evolutionary processes driving heterogeneity within a population. There are transferrable lessons that can be learnt from these studies that will help us to understand the process of intra-tumor heterogeneity in the clinical setting. In this review, we summarize drivers of microbial diversity that have been identified, such as mutation rate and environmental influences, and discuss how knowledge gained from microbial experimental evolution studies may guide us to identify and understand important selective factors that promote intra-tumor heterogeneity. Furthermore, we discuss how these factors could be used to direct and optimize research efforts to improve patient care, focusing on therapeutic resistance. Finally, we emphasize the need for longitudinal studies to address the impact of these potential tumor heterogeneity-promoting factors on drug resistance, metastatic potential and clinical outcome.
Tài liệu tham khảo
Nowell PC: The clonal evolution of tumor cell populations. Science. 1976, 194: 23-28.
Polyak K: Is breast tumor progression really linear?. Clin Cancer Res. 2008, 14: 339-341.
Yates LR, Campbell PJ: Evolution of the cancer genome. Nat Rev Genet. 2012, 13: 795-806.
Horswell S, Matthews N, Swanton C: Cancer heterogeneity and “The Struggle for Existence”: Diagnostic and analytical challenges. Cancer Lett. 2012
Swanton C: Intratumor heterogeneity: evolution through space and time. Cancer Res. 2012, 72: 4875-4882.
Burrell RA, McGranahan N, Bartek J, Swanton C: The causes and consequences of genetic heterogeneity in cancer evolution. Nature. 2013, 501: 338-345.
Gerlinger M, Swanton C: How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br J Cancer. 2010, 103: 1139-1143.
Junttila MR, de Sauvage FJ: Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013, 501: 346-354.
Murugaesu N, Chew SK, Swanton C: Adapting clinical paradigms to the challenges of cancer clonal evolution. Am J Pathol. 2013, 182: 1962-1971.
Gorunova L, Hoglund M, Andren-Sandberg A, Dawiskiba S, Jin Y, Mitelman F, Johansson B: Cytogenetic analysis of pancreatic carcinomas: intratumor heterogeneity and nonrandom pattern of chromosome aberrations. Genes Chromosomes Cancer. 1998, 23: 81-99.
Teixeira MR, Heim S: Cytogenetic analysis of tumor clonality. Adv Cancer Res. 2011, 112: 127-149.
Teixeira MR, Pandis N, Bardi G, Andersen JA, Heim S: Karyotypic comparisons of multiple tumorous and macroscopically normal surrounding tissue samples from patients with breast cancer. Cancer Res. 1996, 56: 855-859.
Navin NE, Hicks J: Tracing the tumor lineage. Mol Oncol. 2010, 4: 267-283.
Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA, Velculescu VE, Kinzler KW, Vogelstein B, Iacobuzio-Donahue CA: Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010, 467: 1114-1117.
Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, Swanton C: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012, 366: 883-892.
Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, Cook K, Stepansky A, Levy D, Esposito D, Muthuswamy L, Krasnitz A, McCombie WR, Hicks J, Wigler M: Tumour evolution inferred by single-cell sequencing. Nature. 2011, 472: 90-94.
Govindan R, Ding L, Griffith M, Subramanian J, Dees ND, Kanchi KL, Maher CA, Fulton R, Fulton L, Wallis J, Chen K, Walker J, McDonald S, Bose R, Ornitz D, Xiong D, You M, Dooling DJ, Watson M, Mardis ER, Wilson RK: Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell. 2012, 150: 1121-1134.
Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, Bashashati A, Prentice LM, Khattra J, Burleigh A, Yap D, Bernard V, McPherson A, Shumansky K, Crisan A, Giuliany R, Heravi-Moussavi A, Rosner J, Lai D, Birol I, Varhol R, Tam A, Dhalla N, Zeng T, Ma K, Chan SK: The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012, 486: 395-399.
Nik-Zainal S, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD, Raine K, Jones D, Hinton J, Marshall J, Stebbings LA, Menzies A, Martin S, Leung K, Chen L, Leroy C, Ramakrishna M, Rance R, Lau KW, Mudie LJ, Varela I, McBride DJ, Bignell GR, Cooke SL, Shlien A, Gamble J, Whitmore I, Maddison M, Tarpey PS, Davies HR, Papaemmanuil E: Mutational processes molding the genomes of 21 breast cancers. Cell. 2012, 149: 979-993.
Nik-Zainal S, Van Loo P, Wedge DC, Alexandrov LB, Greenman CD, Lau KW, Raine K, Jones D, Marshall J, Ramakrishna M, Shlien A, Cooke SL, Hinton J, Menzies A, Stebbings LA, Leroy C, Jia M, Rance R, Mudie LJ, Gamble SJ, Stephens PJ, McLaren S, Tarpey PS, Papaemmanuil E, Davies HR, Varela I, McBride DJ, Bignell GR, Leung K, Butler AP: The life history of 21 breast cancers. Cell. 2012, 149: 994-1007.
Maharjan RP, Ferenci T, Reeves PR, Li Y, Liu B, Wang L: The multiplicity of divergence mechanisms in a single evolving population. Genome Biol. 2012, 13: R41-
Kassen R: The experimental evolution of specialists, generalists, and the maintenance of diversity. J Evol Biol. 2002, 15: 173-190. 10.1046/j.1420-9101.2002.00377.x.
Chao L, Cox EC: Competition between high and low mutating strains of Escherichia coli. Evolution. 1983, 37: 125-134. 10.2307/2408181.
Loeb LA: A mutator phenotype in cancer. Cancer Res. 2001, 61: 3230-3239.
Sprouffske K, Merlo LM, Gerrish PJ, Maley CC, Sniegowski PD: Cancer in light of experimental evolution. Curr Biol. 2012, 22: R762-R771.
Calvo F, Sahai E: Cell communication networks in cancer invasion. Curr Opin Cell Biol. 2011, 23: 621-629.
Lu P, Weaver VM, Werb Z: The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol. 2012, 196: 395-406.
Qian BZ, Pollard JW: Macrophage diversity enhances tumor progression and metastasis. Cell. 2010, 141: 39-51.
Lambert G, Estevez-Salmeron L, Oh S, Liao D, Emerson BM, Tlsty TD, Austin RH: An analogy between the evolution of drug resistance in bacterial communities and malignant tissues. Nat Rev Cancer. 2011, 11: 375-382.
Pikor L, Thu K, Vucic E, Lam W: The detection and implication of genome instability in cancer. Cancer Metastasis Rev. 2013, doi: 0.1007/s10555-013-9429-5
Schluter D: Experimental evidence that competition promotes divergence in adaptive radiation. Science. 1994, 266: 798-801.
Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J, Frederick DT, Cooper ZA, Chapman PB, Solit DB, Ribas A, Lo RS, Flaherty KT, Ogino S, Wargo JA, Golub TR: Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012, 487: 500-504.
Kerr B, Riley MA, Feldman MW, Bohannan BJ: Local dispersal promotes biodiversity in a real-life game of rock-paper-scissors. Nature. 2002, 418: 171-174.
Medema JP: Cancer stem cells: the challenges ahead. Nat Cell Biol. 2013, 15: 338-344.
Visvader JE, Lindeman GJ: Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nature Rev Cancer. 2008, 8: 755-768. 10.1038/nrc2499.
Ronce O, Kirkpatrick M: When sources become sinks: migrational meltdown in heterogeneous habitats. Evolution. 2001, 55: 1520-1531.
Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA, Morsberger LA, Latimer C, McLaren S, Lin ML, McBride DJ, Varela I, Nik-Zainal SA, Leroy C, Jia M, Menzies A, Butler AP, Teague JW, Griffin CA, Burton J, Swerdlow H, Quail MA, Stratton MR, Iacobuzio-Donahue C, Futreal PA: The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature. 2010, 467: 1109-1113.
Rainey PB, Travisano M: Adaptive radiation in a heterogeneous environment. Nature. 1998, 394: 69-72.
Vaupel P, Hockel M: Blood supply, oxygenation status and metabolic micromilieu of breast cancers: characterization and therapeutic relevance. Int J Oncol. 2000, 17: 869-879.
Vaupel P, Kallinowski F, Okunieff P: Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 1989, 49: 6449-6465.
Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME, Allard D, Frese KK, Denicola G, Feig C, Combs C, Winter SP, Ireland-Zecchini H, Reichelt S, Howat WJ, Chang A, Dhara M, Wang L, Rückert F, Grützmann R, Pilarsky C, Izeradjene K, Hingorani SR, Huang P, Davies SE, Plunkett W, Egorin M: Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009, 324: 1457-1461.
Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS, Sougnez C, Stewart C, Sivachenko A, Wang L, Wan Y, Zhang W, Shukla SA, Vartanov A, Fernandes SM, Saksena G, Cibulskis K, Tesar B, Gabriel S, Hacohen N, Meyerson M, Lander ES, Neuberg D, Brown JR, Getz G, Wu CJ: Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013, 152: 714-726.
Descamps-Julien B, Gonzalez A: Stable coexistence in a fluctuating environment: an experimental demonstration. Ecology. 2005, 86: 2815-2824. 10.1890/04-1700.
Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, Ritchey JK, Young MA, Lamprecht T, McLellan MD, McMichael JF, Wallis JW, Lu C, Shen D, Harris CC, Dooling DJ, Fulton RS, Fulton LL, Chen K, Schmidt H, Kalicki-Veizer J, Magrini VJ, Cook L, McGrath SD, Vickery TL, Wendl MC, Heath S, Watson MA, Link DC, Tomasson MH: Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012, 481: 506-510.
Levin BR, Lipsitch M, Perrot V, Schrag S, Antia R, Simonsen L, Walker NM, Stewart FM: The population genetics of antibiotic resistance. Clin Infect Dis. 1997, 24: S9-S16.
Wright S: The roles of mutation, inbreeding, crossbreeding and selection in evolution. Proc Sixth Int Congress Genet. 1932, 1: 356-366.
Wright S: Evolution and the Genetics of Populations, Volume 3. 1977, Chicago: University of Chicage Press
Lenski RE, Travisano M: Dynamics of adaptation and diversification: a 10, 000-generation experiment with bacterial populations. Proc Natl Acad Sci U S A. 1994, 91: 6808-6814.
Zeyl C, Mizesko M, de Visser JA: Mutational meltdown in laboratory yeast populations. Evolution. 2001, 55: 909-917.
Buckling A, Kassen R, Bell G, Rainey PB: Disturbance and diversity in experimental microcosms. Nature. 2000, 408: 961-964.
Massey RC, Buckling A: Environmental regulation of mutation rates at specific sites. Trends Microbiol. 2002, 10: 580-584.
Andersson DI: Persistence of antibiotic resistant bacteria. Curr Opin Microbiol. 2003, 6: 452-456.
Lynch M, Burger R, Butcher D, Gabriel W: The mutational meltdown in asexual populations. J Hered. 1993, 84: 339-344.
Soll SJ, Diaz Arenas C, Lehman N: Accumulation of deleterious mutations in small abiotic populations of RNA. Genetics. 2007, 175: 267-275.
Desai MM, Fisher DS: Beneficial mutation selection balance and the effect of linkage on positive selection. Genetics. 2007, 176: 1759-1798.
Gerrish PJ, Lenski RE: The fate of competing beneficial mutations in an asexual population. Genetica. 1998, 102–103: 127-144.
Gudelj I, Weitz JS, Ferenci T, Claire Horner-Devine M, Marx CJ, Meyer JR, Forde SE: An integrative approach to understanding microbial diversity: from intracellular mechanisms to community structure. Ecol Lett. 2010, 13: 1073-1084.
Loewe L, Hill WG: The population genetics of mutations: good, bad and indifferent. Philos Trans R Soc Lond B Biol Sci. 2010, 365: 1153-1167.
Bailey SF, Dettman JR, Rainey PB, Kassen R: Competition both drives and impedes diversification in a model adaptive radiation. Proc Biol Sci. 2013, 280: 20131253-
Harcombe W: Novel cooperation experimentally evolved between species. Evolution. 2010, 64: 2166-2172.
Nadell CD, Foster KR, Xavier JB: Emergence of spatial structure in cell groups and the evolution of cooperation. PLoS Comp Biol. 2010, 6: e1000716-10.1371/journal.pcbi.1000716.
Verbruggen E, El Mouden C, Jansa J, Akkermans G, Bucking H, West SA, Kiers ET: Spatial structure and interspecific cooperation: theory and an empirical test using the mycorrhizal mutualism. Am Nat. 2012, 179: E133-E146.
Spiers AJ, Buckling A, Rainey PB: The causes of Pseudomonas diversity. Microbiology. 2000, 146: 2345-2350.
Herron MD, Doebeli M: Parallel evolutionary dynamics of adaptive diversification in Escherichia coli. PLoS Biol. 2013, 11: e1001490-
Koza A, Moshynets O, Otten W, Spiers AJ: Environmental modification and niche construction: developing O2 gradients drive the evolution of the Wrinkly Spreader. ISME J. 2011, 5: 665-673.
Helling RB, Vargas CN, Adams J: Evolution of Escherichia coli during growth in a constant environment. Genetics. 1987, 116: 349-358.
Le Gac M, Plucain J, Hindre T, Lenski RE, Schneider D: Ecological and evolutionary dynamics of coexisting lineages during a long-term experiment with Escherichia coli. Proc Natl Acad Sci U S A. 2012, 109: 9487-9492.
Flanagan JL, Brodie EL, Weng L, Lynch SV, Garcia O, Brown R, Hugenholtz P, DeSantis TZ, Andersen GL, Wiener-Kronish JP, Bristow J: Loss of bacterial diversity during antibiotic treatment of intubated patients colonized with Pseudomonas aeruginosa. J Clin Microbiol. 2007, 45: 1954-1962.
Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell. 2011, 144: 646-674.
McGranahan N, Burrell RA, Endesfelder D, Novelli MR, Swanton C: Cancer chromosomal instability: therapeutic and diagnostic challenges. EMBO Rep. 2012, 13: 528-538.
Lee A, Endesfelder D, Rowan A, Walther A, Birkbak N, Futreal AP, Downward J, Szallasi Z, Tomlinson I, Kschischo M, Swanton C: Chromosomal instability confers intrinsic multi-drug resistance. Cancer Res. 2011, 71: 1858-1870.
Birkbak NJ, Eklund AC, Li Q, McClelland SE, Endesfelder D, Tan P, Tan IB, Richardson AL, Szallasi Z, Swanton C: Paradoxical relationship between chromosomal instability and survival outcome in cancer. Cancer Res. 2011, 71: 3447-3452.
Glickman MS, Sawyers CL: Converting cancer therapies into cures: lessons from infectious diseases. Cell. 2012, 148: 1089-1098.
Anderson AR, Weaver AM, Cummings PT, Quaranta V: Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Cell. 2006, 127: 905-915.
Loeb LA: Human cancers express mutator phenotypes: origin, consequences and targeting. Nat Rev Cancer. 2011, 11: 450-457.
Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, Leiserson MD, Miller CA, Welch JS, Walter MJ, Wendl MC, Ley TJ, Wilson RK, Raphael BJ, Ding L: Mutational landscape and significance across 12 major cancer types. Nature. 2013, 502: 333-339.
Walter MJ, Shen D, Ding L, Shao J, Koboldt DC, Chen K, Larson DE, McLellan MD, Dooling D, Abbott R, Abbott R, Fulton R, Magrini V, Schmidt H, Kalicki-Veizer J, O'Laughlin M, Fan X, Grillot M, Witowski S, Heath S, Frater JL, Eades W, Tomasson M, Westervelt P, DiPersio JF, Link DC, Mardis ER, Ley TJ, Wilson RK, Graubert TA: Clonal architecture of secondary acute myeloid leukemia. N Engl J Med. 2012, 366: 1090-1098.
Barrett RD, Schluter D: Adaptation from standing genetic variation. Trends Ecol Evol. 2008, 23: 38-44.
Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S, Cosper AK, Akhavanfard S, Heist RS, Temel J, Christensen JG, Wain JC, Lynch TJ, Vernovsky K, Mark EJ, Lanuti M, Iafrate AJ, Mino-Kenudson M, Engelman JA: Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011, 3: 75ra26-
Chmielecki J, Foo J, Oxnard GR, Hutchinson K, Ohashi K, Somwar R, Wang L, Amato KR, Arcila M, Sos ML, Socci ND, Viale A, de Stanchina E, Ginsberg MS, Thomas RK, Kris MG, Inoue A, Ladanyi M, Miller VA, Michor F, Pao W: Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med. 2011, 3: 90ra59-
Godin-Heymann N, Bryant I, Rivera MN, Ulkus L, Bell DW, Riese DJ, Settleman J, Haber DA: Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. Cancer Res. 2007, 67: 7319-7326.
Vikis H, Sato M, James M, Wang D, Wang Y, Wang M, Jia D, Liu Y, Bailey-Wilson JE, Amos CI, Pinney SM, Petersen GM, de Andrade M, Yang P, Wiest JS, Fain PR, Schwartz AG, Gazdar A, Gaba C, Rothschild H, Mandal D, Kupert E, Seminara D, Viswanathan A, Govindan R, Minna J, Anderson MW, You M: EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activity. Cancer Res. 2007, 67: 4665-4670.
Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, Meyerson M, Eck MJ: The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A. 2008, 105: 2070-2075.
Gatenby RA, Silva AS, Gillies RJ, Frieden BR: Adaptive therapy. Cancer Res. 2009, 69: 4894-4903.
Silva AS, Kam Y, Khin ZP, Minton SE, Gillies RJ, Gatenby RA: Evolutionary approaches to prolong progression-free survival in breast cancer. Cancer Res. 2012, 72: 6362-6370.
Taylor TB, Johnson LJ, Jackson RW, Brockhurst MA, Dash PR: First steps in experimental cancer evolution. Evol Appl. 2013, 6: 535-548.
Yap T, Gerlinger M, Futreal A, Pustzai L, Swanton C: Intratumour heterogeneity: seeing the wood for the trees. Sci Transl Med. 2012, 4: 127-ps10
Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM, Parkinson C, Chin SF, Kingsbury Z, Wong AS, Marass F, Humphray S, Hadfield J, Bentley D, Chin TM, Brenton JD, Caldas C, Rosenfeld N: Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature. 2013, 497: 108-112.